Abbott Laboratories
ABTNYSEHealthcareMedical Devices
As of Oct 15, 2026 close
- Market cap
- $182.46B
- P/E (TTM)
- 33.63
- Forward P/E
- 67.40
- Dividend yield
- 2.41%
- 52-week range
- $81.97$132.03
- Volume (live)
- -
- Avg. volume (3M)
- 9.06M
Abbott Laboratories (ABT) Stock Price & Financial Analysis
Abbott Laboratories Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $104.09 - $105.46 |
|---|---|
| 52-Week High | $132.03 |
| 52-Week Low | $81.97 |
| Open | $105.00 |
| Volume (last close) | 12.75M |
| Average Volume (3M) | 9.06M |
| Revenue (TTM) | 46.59B |
|---|---|
| Net Income (TTM) | 5.42B |
| Free Cash Flow (TTM) | 7.82B |
| EPS (TTM) | $3.11 |
| Profit Margin | 11.65% |
| Operating Margin | 15.77% |
| Return on Equity (ROE) | 10.48% |
| Debt to Equity | 0.63 |
| Annual Dividend | $2.52 |
|---|---|
| Dividend Yield | 2.41% |
| Payout Ratio | 81.13% |
| Last Dividend Ex-Date | Oct 15, 2026 |
| Market Cap | 182.46B |
|---|---|
| Shares Outstanding | 1.74B |
| P/E Ratio (TTM) | 33.63 |
| Forward P/E | 67.40 |
| Price to Sales (P/S) | 3.92 |
| Price to Book (P/B) | 3.52 |
| EV/EBITDA | 18.66 |
| 50-Day MA | $105.95 |
|---|---|
| 200-Day MA | $103.01 |
| 1-Year Change | −17.98% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Abbott Laboratories at a Glance
As of the Oct 15, 2026 close, Abbott Laboratories (ABT) has a market capitalization of $182.46B. The stock trades at 33.6× trailing earnings, 67.4× forward earnings and 3.9× sales. Over the trailing twelve months it earned $5.42B on revenue of $46.59B (a 11.7% profit margin) and generated $7.82B of free cash flow. Revenue grew 8.1% year over year.
As of its latest reported balance sheet, it holds $5.10B in cash and securities against $32.61B of debt, a net debt position of $27.50B.
Abbott Laboratories pays a quarterly dividend totaling $2.52 per share a year, a 2.41% yield at the Oct 15, 2026 close, with a 81% payout ratio and 12 consecutive years of dividend increases.
The share price is down 18.0% over the past year. At $104.68 (the Oct 15, 2026 close) it sits within its 52-week range of $81.97 to $132.03, above its 200-day moving average of $103.01.
Based on 20 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $125.50, 19.9% above the Oct 15, 2026 close.
Frequently Asked Questions About Abbott Laboratories
What is the current stock price for ABT?
As of the Oct 15, 2026 close, ABT stock trades at $104.68. The 52-week range is $81.97–$132.03, with a day range of $104.09–$105.46.
What is the P/E ratio for ABT?
As of the Oct 15, 2026 close, Abbott Laboratories's trailing twelve-month (TTM) P/E ratio is 33.6, meaning investors pay $33.6 for every $1 of annual earnings. The forward P/E is 67.4, reflecting analyst expectations for future earnings. Abbott Laboratories operates in the Healthcare sector.
Does ABT pay dividends?
Yes, Abbott Laboratories pays a 2.41% annual dividend yield as of the Oct 15, 2026 close ($2.52 per share a year). The trailing twelve-month payout ratio is 81.1%. The most recent ex-dividend date was October 15, 2026.
What do analysts recommend for ABT?
Based on ratings from 20 professional analysts over the last 90 days, the consensus for ABT is Buy. The average 12-month price target is $125.50, a 19.9% upside from the Oct 15, 2026 close of $104.68.
What is the market cap of ABT?
As of the Oct 15, 2026 close, Abbott Laboratories's market capitalization is $182.46B, classifying it as a large-cap company. Abbott Laboratories operates in the Healthcare sector within the Medical Devices industry.